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LIKE rocuronium, vecuronium is an aminosteroid neu-romuscular blocking agent with intermediate duration 
of action.1 Sugammadex is a modified γ-cyclodextrin com-
pound2 that reverses the neuromuscular blockade produced by 
rocuronium,3 vecuronium,4,5 and pipecuronium6 by encapsu-
lating them, making them unavailable to interact with the nico-
tinic acetylcholine receptors at the neuromuscular junction. The 
encapsulation of steroidal relaxants by sugammadex is a one-to-
one molecular interaction depending on the affinity of sugam-
madex for the relaxant,2 on the depth of neuromuscular block 
at the time of antagonism, and on the dose of sugammadex.7 
The affinity of the neuromuscular blocking agent for sugamma-
dex is numerically described by the association constant (Ka). 
The higher the Ka, the greater the affinity. The Ka is 3.1 times 
higher for rocuronium than for vecuronium (1.79 × 107 mol/L 
and 5.72 × 106 mol/L, respectively),8 whereas the dissociation 
constant (Kd), which is the inverse of the association constant, 
is 3.1 times higher for vecuronium than for rocuronium (0.17 
and 0.055 μM, respectively).8 Several investigators compared 
the antagonism with sugammadex of moderate (train-of-four 
[TOF] count of two)4,9 and deep (posttetanic count one to two) 
vecuronium- and rocuronium-induced neuromuscular block.10–
12 Significant dose–response relationships were demonstrated 
What We Already Know about This Topic
• Rocuronium-induced neuromuscular block can be reversed 
with sugammadex 0.5 mg/kg and 1.0 mg/kg when four twitches 
in response to train-of-four stimulation have reappeared
• The affinity of sugammadex for rocuronium is 3.1 times that 
for vecuronium
• Because the neuromuscular blocking potency of vecuronium is 
six times that of rocuronium, fewer vecuronium molecules are 
required to produce similar degrees of neuromuscular block
What This Article Tells Us That Is New
• Sugammadex 0.5 mg/kg did not produce prompt and 
satisfactory neuromuscular recovery when administered 
at a threshold train-of-four count of four after vecuronium 
administration
• Sugammadex 1.0 mg/kg adequately reversed this level of 
block, although recovery took twice as long as has been 
reported after rocuronium
• Recurrent neuromuscular block occurred after treatment of 
this level of block with sugammadex doses of 0.5 to 2.0 mg/kg
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ABSTRACT
Background: Rocuronium-induced neuromuscular block that spontaneously recovered to a train-of-four count of four can be 
reversed with sugammadex 0.5 or 1.0 mg/kg. We investigated whether these doses of sugammadex can also reverse vecuronium 
at a similar level of block.
Methods: Sixty-five patients were randomly assigned, and 64 were analyzed in this controlled, superiority study. Participants 
received general anesthesia with propofol, sevoflurane, fentanyl, and vecuronium. Measurement of neuromuscular function 
was performed with acceleromyography (TOF-Watch-SX, Organon Teknika B.V., The Netherlands ). Once the block recov-
ered spontaneously to four twitches in response to train-of-four stimulation, patients were randomly assigned to receive 
sugammadex 0.5, 1.0, or 2.0 mg/kg; neostigmine 0.05 mg/kg; or placebo. Time from study drug injection to normalized 
train-of-four ratio 0.9 and the incidence of incomplete reversal within 30 min were the primary outcome variables. Secondary 
outcome was the incidence of reparalysis (normalized train-of-four ratio less than 0.9).
Results: Sugammadex, in doses of 1.0 and 2.0 mg/kg, reversed a threshold train-of-four count of four to normalized train-of-
four ratio of 0.9 or higher in all patients in 4.4 ± 2.3 min (mean ± SD) and 2.6 ± 1.6 min, respectively. Sugammadex 0.5 mg/kg 
reversed the block in 6.8 ± 4.1 min in 70% of patients (P < 0.0001 vs. 1.0 and 2.0 mg/kg), whereas neostigmine produced 
reversal in 11.3 ± 9.7 min in 77% of patients (P > 0.05 vs. sugammadex 0.5 mg/kg). The overall frequency of reparalysis was 
18.7%, but this incidence varied from group to group.
Conclusions: Sugammadex 1.0 mg/kg, unlike 0.5 mg/kg, properly reversed a threshold train-of-four count of four vecuronium-
induced block but did not prevent reparalysis. (Anesthesiology 2017; 127:441-9)
Reversal of Vecuronium-induced Neuromuscular 
Blockade with Low-dose Sugammadex at Train-of-four 
Count of Four
A Randomized Controlled Trial
László Asztalos, M.D., Zoltán Szabó-Maák, M.D., András Gajdos, M.D., Réka Nemes, M.D.,  
Adrienn Pongrácz, M.D., Ph.D., Szabolcs Lengyel, Ph.D., D.Sci., Béla Fülesdi, M.D., Ph.D., D.Sci., 
Edömér Tassonyi, M.D., Ph.D., D.Sci.
Perioperative Medicine
Copyright © 2017, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Anesthesiology 2017; 127:441-9 442 Asztalos et al.
Reversal of Vecuronium Block with Low-dose Sugammadex 
for mean recovery times to TOF ratio 0.9 with sugammadex 
0.5, 1.0, 2.0, 4.0, and 8.0 mg/kg showing slower recovery from 
vecuronium-induced (35.0 vs. 1.7 min) than from rocuronium-
induced neuromuscular block (16.0 vs. 1.1 min).9,10 Also, 
recurrence of acceleromyographic neuromuscular block (TOF 
ratio less than 0.9) was reported to occur in some patients who 
received low doses of sugammadex for the reversal of moderate 
or deep neuromuscular block.9,10,12 However, the comparative 
literature on this topic is scant. For example, we do not know 
whether low-dose sugammadex would properly reverse a shal-
low vecuronium-induced neuromuscular block and whether 
it would prevent a recurrent block. It has been demonstrated 
that a threshold TOF count-of-four rocuronium-induced neu-
romuscular block can be reversed with sugammadex 1.0 mg/kg 
within 2.1 min, and sugammadex 0.5 mg/kg reversed such 
neuromuscular block in 4.1 min on average.13 These data, how-
ever, may not be valid for vecuronium. Because the neuromus-
cular potency of vecuronium is six times greater than that of 
rocuronium (ED95 = 0.05 and 0.30 mg/kg, respectively)
1 and 
their molecular weight is similar (637 and 610 Da, respec-
tively, http://www.scbt.com/datasheet-205880.html; accessed 
December 15, 2015), fewer vecuronium than rocuronium 
molecules produce similar degrees of neuromuscular block. 
To encapsulate 1.0 mg vecuronium 3.4 mg of sugammadex is 
necessary, and to encapsulate the intubating dose (e.g., 7.0 mg), 
2.4 mg sugammadex is sufficient. Theoretically, a sugam-
madex dose as low as 0.5 mg/kg is enough to encapsulate all 
vecuronium molecules present in the body at any time after 
the administration of vecuronium 0.10 mg/kg. Although the 
affinity of vecuronium for sugammadex is lower than that of 
rocuronium, we hypothesized that the above-described factors 
may partially compensate the lower affinity of vecuronium, 
and thus low doses of sugammadex would adequately reverse a 
threshold TOF count-of-four vecuronium-induced neuromus-
cular block.
Materials and Methods
Trial Design and Participants
This single-center, randomized, controlled, five paral-
lel-arm, superiority trial was approved by the local eth-
ics committee at the University of Debrecen (Debrecen, 
Hungary) and by the National Institute of Pharmaceutics 
(Budapest, Hungary; OGYI/3194–8/2014). The study 
is classified under European Clinical Trials Database No. 
2013-004666-34.
The investigations and data collections were carried out at 
the University Hospital of Debrecen (Debrecen, Hungary) 
between April 2015 and May 2016. The study followed the 
Consolidated Standards of Reporting Trials 2010 recommen-
dations for randomized controlled trials (http://www.consort-
statement.org/consort-2010; accessed June 16, 2017).
Seventy patients undergoing routine elective surgery 
were assessed for eligibility, and 65 were enrolled in this 
study (fig. 1). The study staff recruited the participants at 
the University Hospital of Debrecen. Entrants gave writ-
ten, informed consent to participate. They were randomly 
assigned to one of the five study groups to receive sugam-
madex 0.5, 1.0, or 2.0 mg/kg, neostigmine 0.05 mg/kg 
and atropine 0.015 mg/kg, or 0.9% saline (placebo; fig. 1). 
Inclusion criteria were age of 18 to 65 yr, body mass index 
18.5 to 25.0 kg/m2, American Society of Anesthesiologists 
physical status I to III, male/female ratio 1:1, and scheduled 
for elective surgery with an expected duration of at least 
50 min necessitating muscle relaxant administration for 
intubation of the trachea but not always full relaxation for 
surgery. Exclusion criteria were suspected difficult airway, 
bronchial asthma, chronic obstructive pulmonary disease, 
neuromuscular disease, suspected malignant hyperther-
mia, significant hepatic or renal dysfunction, glaucoma, 
allergy to the drugs used in this study, and taking medica-
tion known to alter the effect of neuromuscular blocking 
agents. Patients who participated in another study within 
30 days were not included, nor were pregnant or breastfeed-
ing women.
Interventions and Neuromuscular Monitoring
Patients were given 7.5 mg midazolam orally 60 min before 
induction of anesthesia. In the operating room, an IV can-
nula was inserted in a forearm vein, and vital signs moni-
toring was started. The patients then received prophylactic 
antibiotic in the form of cefazoline (2 g), cefotaxime (2 g), or 
metronidazole (500 mg) depending on the type of surgery. 
Anesthesia was induced with IV propofol (1.5 to 2.0 mg/
kg) and fentanyl (2.0 μg/kg) and maintained with inhaled 
sevoflurane (1.5 to 1.8 vol%) in air–oxygen mixture supple-
mented with IV fentanyl according to clinical need. Patients’ 
lungs were manually ventilated with oxygen using a face-
mask until intubation of the trachea. Oxygen saturation 
was maintained above 96%, normocapnia was ensured, and 
esophageal temperature was maintained above 36°C using 
forced-air warming system (Bair-Hugger, Arizant Healthcare 
Inc., USA). Neuromuscular monitoring was carried out using 
TOF-Watch-SX acceleromyograph (Organon Teknika B.V., 
The Netherlands). The adductor pollicis muscle contractions 
in response to ulnar nerve stimulation were recorded. The 
piezoelectric probe of the acceleromyograph was attached to 
the tip of the thumb. A hand adapter ensured preload of the 
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thumb while making sure that it continued to return to its 
original position. The forearm and the fingers were immobi-
lized, and surface skin electrodes were placed over the ulnar 
nerve proximal to the wrist. A TOF mode of stimulation was 
started and repeated every 15 s for 3 min followed by a 5-s 
tetanic train of 50 Hz to stabilize the signal. Two minutes 
later automatic calibration was carried out (calibration-2 
to set out supramaximal current intensity and to calibrate 
the device). TOF stimulation was recommenced delivering 
supramaximal square wave stimuli of 0.2 ms duration at 2 
Hz frequency until the signal was stable. If the signal was not 
stable, the calibration was repeated. Data were recorded and 
stored on a computer using TOF-Watch-SX software version 
2.2 INT (Organon Ireland Ltd., Ireland). Skin temperature 
was measured at the forearm near the wrist and maintained 
above 32°C. Once the neuromuscular recording was stable, 
vecuronium 0.10 mg/kg (2 times ED95) was injected IV, and 
the trachea was intubated when the muscle response to TOF 
stimulation disappeared. If surgical relaxation was necessary, 
vecuronium 0.015 to 0.02 mg/kg was administered when 
one to two twitches to TOF stimulation returned. The TOF 
stimulation was automatically delivered at every 15-s interval.
Reversal of a Threshold TOF Count-of-four Block
When four twitches in response to TOF stimulation reap-
peared at three consecutive TOF measurements (a threshold 
TOF count of four), a designated anesthesiologist injected the 
study drug on the request of the attending anesthesiologist 
responsible for the patient and for the study, which was blinded 
to the injected study drug. The evolution of TOF ratio (T4/
T1) and T1 amplitude (the first of four twitches to TOF stimu-
lation) was followed online every 15 s and was also recorded 
for later analysis. Once the displayed TOF ratio reached at 
least 1.0 (unchanged during 3 min), inhaled sevoflurane was 
discontinued and the trachea was extubated when the patients 
emerged from anesthesia. If normalized TOF ratio 0.9 was not 
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Fig. 1. Study flowchart. The administration of sugammadex, neostigmine, and placebo was randomized and double blinded. The 
administration of vecuronium was open. nTOF 0.9 = normalized train-of-four ratio 0.9. Light gray quadrangles show comparison 
for recovery times; dark gray quadrangles show those excluded from comparison of recovery times; rescue sugammadex = 2 mg/
kg. Intraop = intraoperative; Postop = postoperative.
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reached within 30 min after the study drug injection (time was 
agreed on a priori to wait for recovery), incomplete reversal 
was considered, and rescue reversal was given (rescue sugam-
madex 2.0 mg/kg). During this time period the patient’s tra-
chea remained intubated. Adequate reversal was defined as 
average time of 5 min or less from the start of the study drug 
injection to the normalized TOF ratio 0.9.
Postoperative Assessment of Neuromuscular Block
After extubation of the trachea, patients were transferred to 
the recovery room. During the transport, the nerve stimula-
tor was set on standby mode, the forearm and hand adapt-
er’s positioning was secured, and oxygen was administered 
by facemask. In the recovery room, vital signs monitoring 
was continued, and oxygen was delivered via a nasal can-
nula. A second designated anesthesiologist recommenced 
the acceleromyography without recalibration of the device 
(time zero). The measurements were repeated every 20 min 
for 60 min. At each point in time, three consecutive TOF 
stimuli were delivered at 15-s intervals, and their average 
value was considered. Postoperative recurrent neuromus-
cular block was defined as the reappearance of normalized 
TOF ratios less than 0.9. Patients were surveyed for muscle 
weakness, force of coughing, ease of swallowing, and critical 
respiratory or circulatory events and would be immediately 
treated had such complications occurred. Supplementary 
oxygen administration, balloon-mask ventilation, equip-
ment for intubation of the trachea, and rescue sugamma-
dex were available. After discharge from the recovery room, 
patients were observed by the study team for 24 h to detect 
late adverse events.
Outcome Measures
Normalized TOF ratios of 0.9 were calculated and assessed 
as efficacy variables. Normalization was carried out by divid-
ing the recorded values at recovery by baseline values before 
administration of vecuronium.14
Primary outcome measures of the study were the time 
from the start of the injection of the study drug to normal-
ized TOF ratio of 0.9 characterized the effectiveness of rever-
sal and the incidence of no recovery to normalized TOF ratio 
0.9 within 30 min characterized the incomplete reversal.
Secondary outcome measure of the study was the inci-
dence of postoperative recurrent neuromuscular block in the 
recovery room during the first 60 min.
Additional outcome measures were the times from study 
drug injection to recovery of T1 90% to nonnormalized 
TOF ratio 1.0 and the number of patients reaching normal-
ized TOF ratio 1.0
Sample Size
Calculation of sample size was carried out assuming that 
the usual time for recovery is 600 s with an SD of 200 s in 
patients treated with neostigmine and that sugammadex 
0.5 mg/kg decreases the time of recovery to 300 s. Using a 
type I error rate (α) of 0.05, 10 subjects in the treatment 
groups would be needed to reach a power of 0.8. Because we 
assumed that dropouts might occur, we included 13 patients 
in each group, bringing the total to 65 patients.
Randomization and Blinding
The nature of randomization was 1:1 to obtain equal-sized 
study groups. The study statistician generated the random-
ization sequence using a Web-based online program (http://
www.randomizer.org; accessed June 16, 2017). The study 
staff enrolled participants. A designated anesthesiologist pos-
sessed the randomization code, which assigned participants 
to intervention. The designated anesthesiologist prepared 
the study drug and injected it at the request of the attend-
ing anesthesiologist. The size and color of the syringes were 
similar to each other. Participants, the attending anesthesi-
ologist, and the anesthesiologist who performed the postop-
erative acceleromyographic measurements were blinded after 
assignment to interventions.
Statistical Analysis
To analyze the primary outcome of time from the start of 
injection of the study drug to normalized TOF ratio of 0.9, 
we used one-way ANOVA. We examined the assumptions 
of ANOVA using the Shapiro–Wilk W test for the control 
of normal distribution of variables and the Levene test to 
check the homogeneity of variances among the study groups. 
Because the assumptions of normality or homoscedasticity 
were not met by the data, we applied the Box–Cox transforma-
tion for evaluating the primary outcome variable. When vari-
ances differed even after transformation, we used the Welch 
F test for unequal variances. Post hoc testing of differences 
among group means was based on the Tukey honest signifi-
cant difference (HSD) test. We also used ANOVA to analyze 
baseline variables (patient data and perioperative variables) 
when the assumptions of parametric tests were met by the 
data. Otherwise, we used the nonparametric Kruskal–Wallis 
ANOVA to compare groups. For comparing proportions, 
including the primary outcome measure of the incidence of 
incomplete reversals and the secondary outcome measure of 
the incidence of reparalysis, we used the chi-square statistic. 
When the assumptions of the chi-square statistic were not 
met, we applied the Cramer V statistic of association. Because 
there were two components of the primary endpoint, we used 
α level of 0.025 (or half of the conventional α level of 0.05) 
to infer significance in analyses of outcome variables. We used 
α of 0.05 as a significance level in tests of baseline variables. 
All of the statistical calculations were implemented in PAST 
3.0.79 (Øyvind Hammer, Sweden) or in R (version 3.2.2; 
http://www.r-project.org; accessed August 14, 2015).
Results
Seventy patients were eligible, and 65 agreed to partici-
pate in the trial. All of the enrolled patients were assigned 
to one of the five study groups (fig. 1). One patient in the 
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sugammadex 1.0 mg/kg group was excluded from the study 
due to technical failure (broken acceleromyographic device), 
thus the data from 64 cases were analyzed. The trial ended as 
anticipated, after the 24-h-long observation period after the 
tracheal extubation of the last patient.
There were no differences in sex, age, body mass index, 
control TOF ratio, control T1 (%), American Society of 
Anesthesiologists physical status score, or the duration of 
surgery among the five study groups (table 1). There were 
no differences among groups in the dose of vecuronium and 
in the end-tidal sevoflurane concentrations at antagonism. 
There were likewise no differences among groups in the time 
intervals from last vecuronium injection to a threshold TOF 
count of four blocks (table 2).
Primary Outcome
Reversal with neostigmine took 11.3 min, signifi-
cantly longer than reversal with sugammadex 1.0 mg/kg 
(4.4 min) or 2.0 mg/kg (2.6 min; table  3, Tukey HSD 
test for both comparisons, P < 0.05), whereas the dif-
ference between neostigmine and 0.5 mg/kg sugamma-
dex (6.8 min) was not statistically significant (P > 0.05; 
table  3). However, the variance in time to TOF ratio of 
0.9 was significantly larger in the neostigmine group 
(94.1) than in the 0.5 mg/kg sugammadex group (16.6; 
F = 5.671; P = 0.023). Within the sugammadex groups, 
there were significant differences in the times to nor-
malized TOF ratio 0.9 because these times were shorter 
in the groups receiving sugammadex 1.0 or 2.0 mg/kg 
Table 1. Comparison of Baseline Characteristics, Duration of Surgery, and Control Acceleromyographic Values
Variable*
Sugammadex
0.5 mg/kg
Sugammadex
1.0 mg/kg
Sugammadex
2.0 mg/kg
Neostigmine
0.05 mg/kg
Placebo
0.9% Saline P Value
Sex (male/female) 7/6 6/7 7/6 6/7 5/8 0.93†
Age, yr 47 ± 11.6 41 ± 10.1 48 ± 12.9 43 ± 12.4 48 ± 13.5 0.43‡
BMI, kg/m2 22.9 (21.5–24.1) 21.6 (20.1–23.8) 24.6 (21.6–25.1) 24.5 (21.1–24.9) 24.4 (23.2–24.9) 0.17§
Duration of surgery, min 75 (50–113) 45 (38–73) 80 (45–95) 60 (52.5–75) 60 (55–105) 0.34§
Control TOF ratio 1.07 (1.05–1.12) 1.10 (1.04–1.15) 1.07 (1.01–1.11) 1.07 (1.04–1.12) 1.06 (1.03–1.09) 0.77§
Control T1% 96 ± 3.8 99 ± 5.0 98 ± 5.6 96 ± 6.8 100 ± 4.3 0.29‡
ASA class (I/II/III) 3/10/0 5/8/0 4/9/0 6/7/0 4/9/0 0.77†
*Means ± SDs are given when data met the assumptions of parametric statistical tests; otherwise, medians (interquartile ranges) are given. N = 13 in each 
group. †Data are from chi square test. ‡Data are from one-way ANOVA. §Data are from Kruskal–Wallis ANOVA.
ASA = American Society of Anesthesiologists; BMI = body mass index; TOF = train-of-four.
Table 2. Comparison of the Study Groups at Antagonism
Variable*
Sugammadex
0.5 mg/kg
Sugammadex
1.0 mg/kg
Sugammadex
2.0 mg/kg
Neostigmine
0.05 mg/kg
Placebo
0.9% Saline P Value
Total vecuronium dose, mg/kg 0.1 (0.10–0.12) 0.1 (0.10–0.10) 0.1 (0.10–0.11) 0.1 (0.10–0.11) 0.1 (0.10–0.11) 0.44†
Sevoflurane concentration, vol% 1.5 (1.3–1.9) 1.8 (0.9–2.1) 1.6 (1.1–2.0) 1.8 (1.4–1.9) 1.7 (1.4–1.8) 0.99†
Time from last vecuronium dose  
to antagonism, min
53 ± 26 68 ± 33 49 ± 14 50 ± 19 54 ± 23 0.25‡
Normalized TOF ratio 0.10 
(0.07–0.11) [11]
0.09 
(0.07–0.11) [11]
0.10 
(0.10–0.14) [12]
0.09 
(0.08–0.13) [12]
0.09 
(0.07–0.11) [12]
0.76†
Normalized T1% 32 ± 11 31 ± 13 33 ± 10 34 ± 13 31 ± 9 0.94‡
*Means ± SDs are given when data met the assumptions of parametric statistical tests; otherwise, medians (interquartile ranges) are given. Sample size is 
13, except where indicated in brackets. †Data are from Kruskal–Wallis ANOVA. ‡Data are from one-way ANOVA.
TOF = train-of-four.
Table 3. Primary Outcome of the Study
Variable*
Sugammadex
0.5 mg/kg
Sugammadex
1.0 mg/kg
Sugammadex
2.0 mg/kg
Neostigmine
0.05 mg/kg
Placebo
0.9% Saline P Value
Incomplete recovery, n 4 [13] 0 [12] 0 [13] 3 [13] 13 [13] < 0.0001†
Time to normalized TOF 
ratio 0.9, min
6.8 ± 4.1 [9]ab 4.4 ± 2.3 [12]bc 2.6 ± 1.6 [13]c 11.3 ± 9.7 [10]a incomplete  
recovery
< 0.0001‡
Time to T1 90%, min 4.5 ± 3.1 [10] 3.0 ± 2.2 [10] 3.6 ± 4.5 [9] 2.9 ± 1.6 [6] 15.3 ± 6.7 [2] 0.21‡
Time to nonnormalized 
TOF ratio of 1.0, min
8.4 ± 5.8 [8]ab 4.5 ± 2.3 [12]bc 5.1 ± 6.2 [13]c 12.8 ± 9.1 [10]a incomplete  
recovery
< 0.0001‡
*Means ± SDs are given for time variables. Group means not sharing superscript letters differ significantly (Tukey HSD test, P < 0.05). Sample sizes are given 
in brackets. †Data from Cramer’s V. ‡Data from one-way ANOVA.
HSD = honest significant difference; TOF = train-of-four.
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(4.4 and 2.6 min, respectively) than in the sugammadex 
0.5 mg/kg group (6.8 min; table  3; one-way ANOVA for 
the three sugammadex groups, F2,31 = 12.450, P = 0.0001, 
Tukey HSD tests, P < 0.05 for both comparisons). Calcula-
tions of the mean differences between pairs of study groups 
(table 4) confirmed these results and additionally showed 
a significant difference between the sugammadex 1.0 and 
2.0 mg/kg groups (Tukey HSD test, P = 0.047).
The number of incomplete reversals was 4 in the 
sugammadex 0.5 mg/kg group, 3 in the neostigmine 
group, 13 in the placebo group, and 0 in the sugamma-
dex 1.0 and 2.0 mg/kg groups (table 3). The difference 
in incomplete reversals between the placebo and the four 
treatment groups combined was significant (Fisher exact 
P < 0.0001), whereas the difference between the sugam-
madex 0.5 mg/kg group and the neostigmine group was 
not significant (Fisher exact P = 0.157). Calculations of 
odds ratios also confirmed the differences between the 
placebo and each of the four treatment groups (table 4). 
All of the patients with incomplete reversal received res-
cue sugammadex 2.0 mg/kg and recovered to normalized 
TOF ratio 0.9 thereafter. These patients were not consid-
ered for the analysis of reversal times but were included 
in the assessment of the postoperative recurrent neuro-
muscular block.
Secondary Outcome
Postoperative recurrent neuromuscular block occurred in 
12 patients: 3 were in the sugammadex 0.5 mg/kg group, 
4 in the sugammadex 1.0 mg/kg group, 2 in the sugamma-
dex 2.0 mg/kg group, 1 in the neostigmine group, and 2 in 
the placebo group (table 5). These proportions did not differ 
significantly among the groups (chi-square = 2.708, degrees 
of freedom = 4, P = 0.608). Similarly, odds ratios pertain-
ing to the occurrence of reparalysis did not differ in either 
of the pairwise comparisons of study groups (table 4). The 
within-patient variation among the three separated TOF 
measurements was analyzed in each of the 18 reparalyses. 
The median coefficient of variation was 6.0% (interquartile 
range of 5.1%), whereas the geometric mean of the percen-
tual coefficient of variation was 5.2. Precision of TOF mea-
surement was deemed satisfactory if the discrepancy between 
repeated observations was within two times 5.2.14 (Supple-
mental Digital Content, http://links.lww.com/ALN/B488). 
Of the 12 patients with postoperative recurrent neuromus-
cular block, four were asymptomatic (normalized TOF 
ratios 0.85, 0.87, 0.86, and 0.89). Eight patients with TOF 
ratios 0.85, 0.86, 0.83, 0.85, 0.86, 0.86, 0.74, and 0.72 
complained about muscle weakness, which was associated 
with weakened coughing in seven, with positive head lift 
test in four, and with difficulty swallowing in four cases. The 
Table 4. Estimates of the Mean Differences (and Their 95% CIs) in the Time from Injection of the Study Drug to Normalized TOF 
Ratio of 0.9 between Pairs of Study Groups and Odds Ratios for the Number of Failed Reversals at 30 min and the Number of Patients 
with PORNB between Pairs of Study Groups
Variable* Study Group
Sugammadex
1.0 mg/kg
Sugammadex
2.0 mg/kg
Neostigmine
0.05 mg/kg
Placebo
0.9% Saline
Time to normalized 
TOF ratio of 0.9
Sugammadex 
0.5 mg/kg
–2.5  
(–8.6 to 3.6)
–4.2 (–10.2 to 1.8)† 4.4 (–1.9 to 10.8) –
Sugammadex 
1.0 mg/kg
— –1.7 (–7.3 to 3.8)‡ 6.9 (1.0 to 12.8)‡ –
Sugammadex 
2.0 mg/kg
— — 8.6 (2.8 to 14.4)§ –
No. of incomplete 
reversals at 30 min
Sugammadex 
0.5 mg/kg
11.84  
(0.57 to 247.85)
12.79 (0.61 to 266.67) 1.48 (0.26 to 8.50) 0.018 (0.00 to 0.37)†
Sugammadex 
1.0 mg/kg
— 1.08 (0.02 to 58.66) 0.12 (0.01 to 2.60) 0.002 (0.00 to 0.08)†
Sugammadex 
2.0 mg/kg
— — 0.11 (0.01 to 2.40) 0.001 (0.00 to 0.07)†
Neostigmine 
0.05 mg/kg
— — — 0.012 (0.00 to 0.27)†
No. of patients with 
recurrent block
Sugammadex 
0.5 mg/kg
0.67  
(0.11 to 3.93)
1.67 (0.23 to 12.35) 4.00 (0.36 to 45.10) 1.833 (0.25 to 13.47)
Sugammadex 
1.0 mg/kg
— 2.50 (0.36 to 17.3) 6.00 (0.56 to 63.99) 2.750 (0.40 to 18.88)
Sugammadex 
2.0 mg/kg
— — 2.40 (0.19 to 30.52) 1.100 (0.13 to 9.34)
Neostigmine 
0.05 mg/kg
— — — 0.458 (0.04 to 5.79)
As an example, the time to normalized TOF ratio of 0.9 was, on average, 2.5 min shorter in the sugammadex 1.0 mg/kg group than in the sugammadex 
0.5 mg/kg group.
*Estimates (95% CIs) of the mean differences between study groups are given for time to normalized TOF ratio of 0.9, and odds ratios (95% CIs) are given 
for number of failed reversals and number of patients with reparalysis. Tukey honest significant difference test was used for P values. ‡P < 0.05. †P < 0.01. 
§P < 0.001.
PORNB = postoperative recurrent neuromuscular block; TOF = train-of-four.
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duration of recurrent block was 40 min in one subject and 
20 min in the others. The lowest TOF ratios were measured 
at 60 min, one in the sugammadex 2.0 mg/kg group (nor-
malized TOF ratio 0.72) and one in the placebo group (nor-
malized TOF ratio 0.74) after rescue sugammadex 2.0 mg/
kg. Both patients complained about muscle weakness; they 
had weakened coughing, difficulty swallowing, positive 
head-lift test, and difficulty in eye movement. Discharge of 
these patients from the recovery room was delayed by 20 to 
30 min until they became asymptomatic.
Additional Outcome
The number of patients reaching normalized TOF ratio 1.0 
was 2, 4, 5, 2, and 0 in the sugammadex 0.5, 1.0, 2.0 mg/
kg; neostigmine; and placebo groups, respectively. The times 
to reach nonnormalized TOF ratio 1.0 did not differ sig-
nificantly from the times to reach normalized TOF ratio 
0.9. There was no difference among the treatment groups in 
times to achieve T1 90% (table 3).
Harms
No important harms or adverse effects were observed.
discussion
Summary of Results
The current study investigated whether sugammadex 0.5 and 
1.0 mg/kg adequately reverses a vecuronium-induced neu-
romuscular block that spontaneously returned to a thresh-
old TOF count of four. Criterion of adequate reversal was 
achievement of normalized TOF ratio 0.9 in 5 min or less 
on average. Incomplete reversal was defined as failure to 
reach normalized TOF ratio 0.9 within 30 min after admin-
istration of reversal agent. Also, the incidence of recur-
rent neuromuscular block (normalized TOF ratios less 
than 0.9) was studied. Sugammadex 1.0 mg/kg adequately 
reversed the block in each patient, as did the standard dose 
(2.0 mg/kg). Of the 13 patients who received sugammadex 
0.5 mg/kg, 4 produced incomplete reversal. The mean reversal 
time for the remaining nine patients was 6.8 min, thus it did 
not fulfill the criterion of adequate reversal. Neostigmine was 
not significantly different from sugammadex 0.5 mg/kg, with a 
mean reversal time of 11.3 min in 10 patients and with incom-
plete reversal in 3 patients. Recurrent block was detected in 12 
patients. These results do not support our hypothesis that a 
threshold TOF count-of-four vecuronium-induced neuromus-
cular block can adequately be reversed with limited sugamma-
dex doses similar to a rocuronium-induced block.13
There are two reasons to use a small-dose of sugamma-
dex for reversal of residual neuromuscular block. The first is 
an economic one, attempting to decrease the costs required 
for sugammadex treatment.13 The second is that too much 
sugammadex on board would limit the options should rein-
tubation of the trachea or repeat surgery be needed shortly 
after the end of the case.15,16 However, the concept of reversal 
of residual neuromuscular block with clinically limited dose 
range of sugammadex generated concern about reparalysis, 
arguing that sugammadex 1.0 mg/kg or 0.5 mg/kg is insuffi-
cient to restore the safety margin of the neuromuscular junc-
tion; thus, rebound of the block may happen.17,18 Actually 
only a few studies have investigated the effect of low-dose 
sugammadex on the reversal of shallow residual neuromuscu-
lar blocks.19 What we know about this topic is that 0.25 mg/
kg of sugammadex is able to reverse a rocuronium-induced 
Table 5. Secondary Outcome of the Study: Incidence of Postoperative Reparalysis during the First 60 min in the Recovery Room
Variable Measure
Sugammadex
0.5 mg/kg
Sugammadex
1.0 mg/kg
Sugammadex
2.0 mg/kg
Neostigmine
0.05 mg/kg
Placebo
0.9% Saline
Time from 
 extubation to 
first TOF meas-
urement, min*
Median (IQR) 23.2 (19.8–28.2) 24.5 (21.0–27.2) [12] 23.3 (16.0–30.8) 24.9 (18.8–35.9) 21.9 (16.5–26.8)
Normalized TOF 
ratios at 0 min
Mean ± SD 1.01 ± 0.09 0.96 ± 0.09 1.01 ± 0.08 1.05 ± 0.09 1.01 ± 0.05
95% CI 0.96–1.06 0.91–1.01 0.97–1.06 1.00–1.10 0.98–1.03
Median (range) 0.99 (0.85–1.27) 0.95 (0.83–1.11) 1.02 (0.85–1.19) 1.04 (0.95–1.33) 1.00 (0.96–1.10)
Normalized TOF 
ratios at 20 min
Mean ± SD 1.04 ± 0.15 1.01 ± 0.09 1.01 ± 0.05 1.04 ± 0.10 1.00 ± 0.06
95% CI 0.96–1.12 0.96–1.06 0.98–1.04 0.98–1.09 0.96–1.03
Median (range) 1.03 (0.84–1.42) 1.01 (0.85–1.15) 1.02 (0.92–1.10) 1.01 (0.86–1.28) 1.01 (0.89–1.11)
Normalized TOF 
ratios at 40 min
Mean ± SD 0.99 ± 0.08 0.98 ± 0.07 1.01 ± 0.06 1.04 ± 0.07 1.03 ± 0.08
95% CI 0.95–1.04 0.94–1.02 0.98–1.04 1.00–1.08 0.98–1.07
Median (range) 1.01 (0.86–1.14) 0.97 (0.87–1.09) 1.02 (0.92–1.08) 1.04 (0.96–1.17) 1.02 (0.86–1.16)
Normalized TOF 
ratios at 60 min
Mean ± SD 1.04 ± 0.13 0.99 ± 0.08 1.00 ± 0.13 1.03 ± 0.07 1.04 ± 0.12
95% CI 0.97–1.12 0.95–1.04 0.93–1.08 0.99–1.06 0.97–1.11
Median (range) 0.99 (0.91–1.32) 1.00 (0.86–1.13) 0.99 (0.72–1.26) 1.03 (0.91–1.12) 1.05 (0.74–1.31)
Recurrent block Yes/no 3/9 4/8 2/10 1/12 2/11
Medians (interquartile ranges) are given for time between the last TOF measurement in the operating room and the first TOF measurement in the recovery 
room (time 0 min). Means ± SDs and medians (range) of normalized TOF ratios at four points in time in the recovery room are given. The number of patients 
with and (without) postoperative recurrent neuromuscular block in the study groups is shown. *Kruskal–Wallis H = 2.611, P = 0.625.
IQR = interquartile range; TOF = train-of-four.
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block at a TOF ratio of 0.5 to 0.9 in an average time of 
less than 2 min7 and that sugammadex 1.0 or 0.5 mg/kg 
adequately reversed a threshold TOF count-of-four 
rocuronium-induced block under sevoflurane anesthesia.13 
Also, moderate (T2) rocuronium- and vecuronium-induced 
neuromuscular blocks were successfully reversed under pro-
pofol–remifentanil anesthesia.4
A multicenter study9 demonstrated a clear dose–response 
relationship for the reversal of moderate rocuronium- and 
vecuronium-induced neuromuscular block with sugamma-
dex 0.5, 1.0, 2.0, and 4.0 mg/kg under sevoflurane anes-
thesia. Recovery times to TOF ratio 0.9 were shorter in the 
rocuronium versus the vecuronium group, and the difference 
was the most pronounced at sugammadex 0.5 mg/kg. Recur-
rence of the block occurred in seven patients due to subop-
timal doses of sugammadex but also after the recommended 
dose of 2.0 mg/kg in one case. Duvaldestin et al.10 investigated 
the reversal of deep vecuronium- and rocuronium-induced 
neuromuscular block with increasing doses of sugammadex 
under sevoflurane maintenance anesthesia. Sugammadex 
in doses of 4.0 mg/kg or higher provided rapid reversal of 
deep rocuronium- and vecuronium-induced neuromuscu-
lar block. Neuromuscular monitoring showed recurrence of 
neuromuscular block in five patients, all in the rocuronium 
group (two received 0.5 mg/kg and three received 1.0 mg/
kg sugammadex). Eleveld et al.12 observed the rebound of 
neuromuscular block after attempting to reverse a deep 
rocuronium-induced block with sugammadex 0.5 mg/kg. 
From these studies we know that low-dose sugammadex 
is unsuitable to reverse moderate or deep rocuronium- or 
vecuronium-induced neuromuscular block.
What the present study adds to our knowledge is that 
sugammadex 0.5 mg/kg cannot reverse a threshold TOF 
count-of-four neuromuscular block to normalized TOF 
ratio 0.9 in 30% of the patients, and it is not more effec-
tive than neostigmine in the remaining 70%. We con-
firmed that reparalysis can occur even after the reversal of 
such a neuromuscular block with sugammadex 2.0 mg/kg. 
Therefore, caution is suggested when using limited clinical 
doses of sugammadex (2.0 mg/kg or less) for antagonism of 
vecuronium-induced residual block, and the use of quantita-
tive neuromuscular monitoring is highly recommended.
There may be several explanations for these results. First, 
the complexation of relaxant sugammadex and its break-
down into constituent molecules depends on the propensity 
of the two substances to associate and to dissociate.2 Because 
sugammadex is more selective for rocuronium than for 
vecuronium (Ka = 1.79 × 107 mol/L and 5.72 × 106 mol/L, 
respectively),8 the complexation is slower with vecuronium 
than with rocuronium. Second, because the Kd of vecuronium 
is 0.17 μM versus 0.055 μM for rocuronium,8 higher rela-
tive sugammadex concentrations are required for complex 
formation with vecuronium compared with rocuronium. 
This may explain why sugammadex 0.5 mg/kg was limited 
in reversing the residual effect of vecuronium, in contrast to 
what was previously found with rocuronium.13 Third, the 
sugammadex/vecuronium concentration ratio, not the abso-
lute number of vecuronium molecules in the body, appears 
to be the decisive factor for the reversal of vecuronium block. 
Therefore, sugammadex 1.0 mg/kg and 2.0 mg/kg were effec-
tive, whereas 0.5 mg/kg was not. Furthermore, none of the 
sugammadex doses administered in this study prevented the 
recurrence of neuromuscular block. The overall frequency of 
reparalysis was 18.7%, but this incidence varied from group 
to group. This was an unexpected outcome, which raises the 
suspicion of artifacts due to displacement of the arm during 
the measurement of acceleromyographic TOF responses in 
patients recovering from anesthesia.20 To prevent this bias, 
special care was taken by the study anesthesiologists to ade-
quately fasten the arm during TOF stimulation, like in our 
previous study including 47 awake patients who were moni-
tored for residual neuromuscular blockade during 60 min in 
the recovery room.6 Because these patients presented neither 
clinical signs of residual paralysis nor TOF ratio depression, 
they can be considered as a control group for the current 
study, thus validating its results. With regard to the mecha-
nism of reparalysis, low doses of sugammadex may be suf-
ficient for complex formation with the relaxant molecules 
in the central compartment but are insufficient for redis-
tribution from the periphery to the plasma. Furthermore, 
the dissociation of vecuronium from the complex over time 
(referring to Kd) also takes place and increases the possibil-
ity of rebounding block.12 Although it cannot be excluded 
with certitude, it is less likely that residual concentrations of 
sevoflurane enhanced the block in the postoperative period. 
It is also unlikely that the metabolite of vecuronium caused 
reparalysis; the doses were too small for this. No severe post-
operative reparalysis occurred in the patients, and the major-
ity of recurrent blocks were slight (normalized TOF ratios 
0.83 to 0.89), apparently at the limit of the safety margin.
Clinical signs of reparalysis were observed in 8 patients with-
out other adverse event. Nevertheless, recurrent neuromuscular 
block may be associated with postoperative complications such 
as hypoxia, weakness, pulmonary aspiration of gastric content, 
and respiratory failure. The prevention of these complications 
may improve patient safety and decrease mortality rates.21
Limitation of This Study
This study was based on acceleromyographic measurements of 
neuromuscular transmission, which is known to overestimate 
the recovery. However, we used preload and normalization 
to improve its accuracy.14 Had we considered nonnormal-
ized TOF ratios for postoperative recurrent neuromuscular 
block, five recurrent blocks would have been detected. We 
did not measure the plasma concentrations of sugammadex, 
vecuronium, or 3-desacetylvecuronium, and spirometry was 
not carried out for the diagnosis of possible respiratory depres-
sion. Although the explanation of the result was based on 
published data, presumptions about the mechanism of rever-
sal and postoperative recurrent neuromuscular block could 
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not be avoided. Due to ethical reasons and tight operating 
schedules, a 30-min cutoff point in time was a priori included, 
resulting in reduction of the sample size in three treatment 
groups. Although the placebo control was excluded from the 
comparison of the reversal times, it allowed for distinguishing 
the effect of sugammadex 0.5 mg/kg and neostigmine from 
spontaneous recovery. Of note, the administration of rescue 
treatment to placebo patients confirmed the occurrence of 
postoperative recurrent neuromuscular block after sugamma-
dex 2.0 mg/kg. This issue is clinically relevant and, therefore, 
additional studies are highly desirable to confirm these results.
In conclusion, this study demonstrated that sugamma-
dex 0.5 mg/kg is insufficient to reliably guarantee prompt 
and satisfactory neuromuscular recovery after vecuronium 
administration at a threshold TOF count of four. Increasing 
the dose to 1.0 mg/kg adequately reversed this level of block, 
although recovery took twice as long as has been reported 
after rocuronium. In addition, recurrent neuromuscu-
lar block occurred in each treatment group. Sugammadex 
0.5 mg/kg should not be used for the reversal of vecuronium-
induced neuromuscular block, and the use of quantitative 
neuromuscular monitoring is highly recommended.
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